Comparative Pharmacology
Head-to-head clinical analysis: NAPRELAN versus PHENYLBUTAZONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAPRELAN versus PHENYLBUTAZONE.
NAPRELAN vs PHENYLBUTAZONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which mediates pain, inflammation, and fever.
Phenylbutazone is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, thereby causing anti-inflammatory, analgesic, and antipyretic effects. It also inhibits leukocyte migration and lysosomal enzyme release.
750 mg to 1000 mg orally once daily, with or without food.
Oral: 100-200 mg three times daily with food; maximum 600 mg/day. For acute gout: initial 400 mg followed by 200 mg every 4-6 hours for 1-2 days, then reduce.
None Documented
None Documented
Clinical Note
moderatePhenylbutazone + Gatifloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderatePhenylbutazone + Rosoxacin
"Phenylbutazone may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderatePhenylbutazone + Levofloxacin
"Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderatePhenylbutazone + Trovafloxacin
Terminal elimination half-life: 10-20 hours; context: allows twice-daily or once-daily dosing for chronic pain or inflammation.
Terminal elimination half-life is 50–65 hours, but exhibits dose-dependent kinetics; can extend to 72–100 hours with repeated dosing or in elderly.
Renal: 50-60% as metabolites and conjugates; biliary/fecal: ~5%; remainder uncharacterized.
Primarily hepatic metabolism; renal excretion of metabolites (<1% unchanged). Biliary/fecal excretion accounts for ~20% of total elimination.
Category C
Category C
NSAID
NSAID
"Phenylbutazone may increase the neuroexcitatory activities of Trovafloxacin."